Dissecting the IMpact of 11-OXygenated and Classic Androgens on Skeletal Muscle Insulin Sensitivity (DIMOXIS) (DIMOXIS)
Androgen excess is the cardinal biochemical feature of polycystic ovary syndrome (PCOS). Serum testosterone correlates with insulin resistance in PCOS, however, there is an urgent need to improve our understanding of the association between androgens and the risk of type 2 diabetes.
11-oxygenated steroids are the predominant androgens in PCOS and correlate closely with markers of insulin resistance. The bioactive 11-oxygenated androgen 11-ketotestosterone (11KT) binds and activates the androgen receptor with equal affinity to testosterone, yet nothing is known about its impact on metabolism or glucose homeostasis
Crucially, there are no data linking androgen excess with muscle glucose metabolism and the differential contribution of 11-oxygenated androgens to diabetes risk through these processes remains unknown.
The investigators hypothesise the following:
- Oral androgen exposure in women with PCOS results in distinct changes in tissue-specific insulin sensitivity and muscle energy biogenesis
- 11-oxygenated androgen exposure exerts differential changes on the above parameters in comparison to classic androgen exposure
The study has the following aims:
- To examine the impact of oral androgen exposure on skeletal muscle insulin sensitivity and glucose disposal in women with PCOS.
- To delineate the impact of androgen exposure on muscle mitochondrial function ex vivo in women with PCOS
- To compare the differential impact of 11-oxygenated androgen compared to classic androgens on glucose disposal and muscle mitochondrial function
The two arms will run in parallel and all participants will undergo identical investigations before and after 7 days of either DHEA or 11KA4.
Investigations will include baseline arthrometric measurements muscle biopsy, two-step hyperinsulinaemic euglycaemic clamp, breath sampling.
This interventional metabolic phenotyping study will probe the role of classic and 11-oxygenated androgens in metabolic dysfunction in PCOS using gold-standard in vivo metabolic phenotyping techniques. Delineating the distinct contribution of 11-oxygenated androgens, through effects on skeletal muscle biology, to the risk of T2DM is an important step in the process of determining risk of type 2 diabetes in this vulnerable cohort.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Michael W O'Reilly
- Phone Number: 018093894
- Email: michaelworeilly@rcsi.ie
Study Locations
-
-
-
Dublin 9, Ireland
- Recruiting
- Beaumont Hospital
-
Contact:
- Michael O'Reilly
- Phone Number: 018093894
- Email: michaelworeilly@rcsi.ie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women with a confirmed diagnosis polycystic ovary syndrome with androgen excess on clinical or biochemical grounds
- BMI 20.0-39.9kg/m2
- Age range 18-40 years
- Ability to provide informed consent
Exclusion Criteria:
- A confirmed diagnosis of diabetes
- Current or recent (<3-months) use of weight loss medications
- Current or recent use of oral contraceptive pill or hormone replacement therapy (within 3-months)
- Blood haemoglobin <12.0g/dL
- History of alcoholism or a greater than recommended alcohol intake (recommendations > 21 units on average per week for men and > 14 units on average per week for women)
- Haemorrhagic disorders or Treatment with anticoagulant agents
- Any medical condition in the opinion of the investigator that might impact upon safety or validity of the results
- Pregnancy or breastfeeding at the time of planned recruitment
- A diagnosis of PCOS according to Rotterdam criteria where the patient does not have clinical or biochemical evidence of androgen excess
- History of significant renal (eGFR<30) or hepatic impairment (AST or ALT >two-fold above ULN; pre-existing bilirubinaemia >1.2 ULN)
- Any other significant disease or disorder that, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
- Current intake of drugs known to impact upon steroid or metabolic function or intake of such drugs during the six months preceding the planned recruitment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: DHEA
Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.
|
Dehydroepiandrosterone (DHEA) at a dose of 150mg once daily for 7 days.
|
|
Experimental: 11KA4
Adult females with polycystic ovary syndrome (PCOS) and evidence of clinical or biochemical androgen excess will be recruited and randomised.
|
11ketoandrostenedione (11KA4) at a doses of 150mg once daily for 7 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relative change in glucose disposal from baseline with 11KA4 administration compared to that seen with DHEA
Time Frame: 7 Days
|
Utilizing hyperglycaemic-euglycaemic clamp (μmol/min/kg)
|
7 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Relative change in glucose oxidation from baseline with 11KA4 administration compared to that seen with DHEA
Time Frame: 7 Days
|
Measured by 13C-breath testing (mg/kg/min)
|
7 Days
|
|
Relative change in endogenous glucose production from baseline with 11KA4 administration compared to that seen with DHEA (μmol/min/kg)
Time Frame: 7 Days
|
Utilizing hyperglycaemic-euglycaemic clamp (μmol/min/kg)
|
7 Days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Michael W Michael, RCSI Education & Research Centre, Beaumont Hospital, Beaumont Dublin 9 Ireland Ireland
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Neoplasms
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Hyperinsulinism
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Polycystic Ovary Syndrome
- Insulin Resistance
- Endocrine System Diseases
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- Dehydroepiandrosterone
Other Study ID Numbers
- DIMOXIS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.